Maria Kleppe
Overview
Explore the profile of Maria Kleppe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
2585
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jasmine S, Mandl A, Krueger T, Dalrymple S, Antony L, Dias J, et al.
Prostate
. 2024 Apr;
84(10):909-921.
PMID: 38619005
Introduction: Lysine-specific demethylase 1 (LSD1) is emerging as a critical mediator of tumor progression in metastatic castration-resistant prostate cancer (mCRPC). Neuroendocrine prostate cancer (NEPC) is increasingly recognized as an adaptive...
2.
Rapaport F, Seier K, Neelamraju Y, Hassane D, Baslan T, Gildea D, et al.
Blood Cancer J
. 2023 Jul;
13(1):103.
PMID: 37407550
No abstract available.
3.
Jiang Q, Stachelscheid J, Bloehdorn J, Pacholewska A, Aszyk C, Grotenhuijs F, et al.
Blood
. 2023 Apr;
142(1):44-61.
PMID: 37023372
In chronic lymphocytic leukemia (CLL), epigenetic alterations are considered to centrally shape the transcriptional signatures that drive disease evolution and underlie its biological and clinical subsets. Characterizations of epigenetic regulators,...
4.
Dunbar A, Kim D, Lu M, Farina M, Bowman R, Yang J, et al.
Blood
. 2023 Feb;
141(20):2508-2519.
PMID: 36800567
Proinflammatory signaling is a hallmark feature of human cancer, including in myeloproliferative neoplasms (MPNs), most notably myelofibrosis (MF). Dysregulated inflammatory signaling contributes to fibrotic progression in MF; however, the individual...
5.
Rapaport F, Seier K, Neelamraju Y, Hassane D, Baslan T, Gildea D, et al.
Blood Cancer J
. 2022 Sep;
12(9):137.
PMID: 36151075
No abstract available.
6.
Chen B, Deshpande A, Barbosa K, Kleppe M, Lei X, Yeddula N, et al.
Blood
. 2021 Mar;
137(24):3403-3415.
PMID: 33690798
Leukemias bearing fusions of the AF10/MLLT10 gene are associated with poor prognosis, and therapies targeting these fusion proteins (FPs) are lacking. To understand mechanisms underlying AF10 fusion-mediated leukemogenesis, we generated...
7.
Schmidt T, Kharabi Masouleh B, Loges S, Cauwenberghs S, Fraisl P, Maes C, et al.
Cancer Cell
. 2020 Jan;
37(1):135-136.
PMID: 31935370
No abstract available.
8.
Jutzi J, Kleppe M, Dias J, Staehle H, Shank K, Teruya-Feldstein J, et al.
Hemasphere
. 2019 Nov;
2(3):e54.
PMID: 31723778
Despite recent advances, the myeloproliferative neoplasms (MPNs) are attended by considerable morbidity and mortality. Janus kinase (Jak) inhibitors such as ruxolitinib manage symptoms but do not substantially change the natural...
9.
Comen E, Bowman R, Selenica P, Kleppe M, Farnoud N, Pareja F, et al.
J Natl Cancer Inst
. 2019 Sep;
112(1):107-110.
PMID: 31504684
Chemotherapy and radiation therapy are the foundations of adjuvant therapy for early-stage breast cancer. As a complication of cytotoxic regimens, breast cancer patients are at risk for therapy-related myeloid neoplasms...
10.
Shank K, Dunbar A, Koppikar P, Kleppe M, Teruya-Feldstein J, Csete I, et al.
Haematologica
. 2019 Aug;
105(3):e91-e94.
PMID: 31413098
No abstract available.